Navigation Links
Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
Date:6/2/2008

n first relapse of AML whose first complete remission (CR) was more than three months but less than twenty-four months in duration. Patients were stratified according to: (i) age, greater than or less than 60 years and (ii) length of the first CR, more than or less than 12 months in duration. The primary endpoint for the trial was the objective response rate, defined as CR plus CRp (a complete remission with incomplete recovery of platelet count). Secondary endpoints included time to progression, duration of response, overall survival and toxicity.

Preliminary blinded data for this randomized trial were previously presented at the American Society of Hematology Annual Meeting in December 2006. This was the first presentation of the unblinded data.

About Vion

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) with cytarabine in elderly patients with acute myelogenous leukemia, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from t
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... DC (PRWEB) November 27, 2014 “LAB.C” was ... which features the latest and coolest technology products available to ... conducted the product review and shared with viewers ... for iOS and Android devices. , Consumers love portability and ... Their Cable Case for the iPhone5 and 5S has ...
(Date:11/27/2014)... This is a professional and ... For an overview analysis, the report introduces Insulin ... structure, industry overview, policy analysis, and news analysis, ... covers information on policy, plans for Insulin Market ... much more. , This report also ...
(Date:11/27/2014)... Allowing children to help with chores while ... give children responsibility, ownership, boosts self-esteem, and above all, helps ... the real question is, how do you encourage your children ... a study published by Child Development Journal, there is. The ... on a child’s willingness to lend a hand. , ...
(Date:11/27/2014)... 27, 2014 RBSEO Services, a ... engine optimization service just at $99. RBSEO Services ... cannot afford costly search engine optimization service. So, ... their affordablity and requirements into consideration. , ... it has not compromised with the service quality. ...
(Date:11/27/2014)... Ethane Web Technologies, an ISO 9001: 2008 certified Internet ... discount on PPC service. The discount will be available for ... on 1 December 2014 and remain valid until midnight of ... professional working at Ethane Web Technologies says, "This is a ... big discount would make the service quite affordable for them. ...
Breaking Medicine News(10 mins):Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 3Health News:RBSEO Services Announces SEO Services at $99 Only 2Health News:Ethane Web Technologies Announces 10% Christmas Discount on PPC Service 2
... Researchers aren,t sure why two conditions are connected , WEDNESDAY, ... likely to have heart attacks, a new study shows, but ... still unclear. , The incidence of heart attacks in people ... suffer the headaches, according to a report in the Feb. ...
... quarter of Ontario hospitals surveyed in a Queen,s University-led study ... that do exist have been tested. In addition, key players ... pandemic preparedness was inadequate., "It,s not good enough just to ... to know how well it will work in an emergency," ...
... DES PLAINES, Ill. , Feb. 10 ... for the ENA Leadership Conference to be held in ... All of ENA,s sponsors will be recognized at the upcoming ... Monster.com and Stryker; the Leadership Conference Sponsor, Physio-Control; and the ...
... , ... - Hiru Corporation (HIRU; www.hirucorporation.com ) and its European subsidiary ... about the MindUp and Sabera Ruzdijic,s patents. Dr. Sabera Ruzdijic ... cancer project. The other team leaders in MindUp Research project are ...
... February 10, 2010 The American Society ... as part of its program specifically dedicated to promoting ... practiced in the United States. The ASGE Endoscopy Unit ... guidelines on privileging, quality assurance, endoscopy reprocessing and CDC ...
... ... on celiac disease, one of the most common and under-diagnosed autoimmune diseases, it,s symptoms, and ... patients a year, one being day-time Emmy Award winner, Elisabeth Hasselbeck of ABC’s “The View”. ... (PRWEB) February 11, 2010 ...
Cached Medicine News:Health News:Migraine Linked to Increased Heart Attack Risk 2Health News:Migraine Linked to Increased Heart Attack Risk 3Health News:Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference 2Health News:Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference 3Health News:MindUp (HIRU) Patents in the World Patent Database 2Health News:MindUp (HIRU) Patents in the World Patent Database 3Health News:ASGE recognizes 32 endoscopy units for quality and safety 2Health News:Multi-Award Winning Author Tina Turbin Interviews Special Guest Dr. Peter H.R. Green, M.D. On The Thrive in Balance Radio Show 2
(Date:11/26/2014)... Nov. 26, 2014  Perrigo Company plc ("Perrigo") (NYSE: ... of "Quality Affordable Healthcare Products®," today announced the closing ... the sale of 6,809,210 ordinary shares at a public ... exercise of the option to purchase up to an ... and Barclays Capital Inc., as representatives of the several ...
(Date:11/26/2014)... , Nov. 26, 2014  Genomic Health, Inc. (Nasdaq: ... , Chairman, Chief Executive Officer and President, will participate ... Conference at The New York Palace Hotel in ... at 11:30 am Eastern Time (ET). To ... conference call, go to the  Investor Relations  section of ...
(Date:11/26/2014)... 2014   Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today announced ... CEO of Regulus, will present a company overview at ... at the New York Palace Hotel on Wednesday, December ... be webcast at the time of the presentation and ...
Breaking Medicine Technology:Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 4Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference 2Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference 3Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: